• News
  • SAN DIEGO
  • BioTech

Isis surges on diabetes tests

Shares of Carlsbad’s Isis Pharmaceuticals (NYSE: ISIS) surged on Tuesday evening and Wednesday after the company announced positive results from phase 2 testing of a proposed treatment for diabetes.

The surge came after Isis revealed that its experimental drug, ISIS-GCGRRx, had successfully reduced blood sugar level in test subjects suffering type 2 diabetes who were experiencing uncontrolled blood sugar levels despite receiving standard treatment.

Between Tuesday’s close on Wall Street and the first hour of trading Wednesday morning, Isis stock surged more than 11 percent, rising from $25.09 to $27.92. But during the next hour, profit-taking set in so that by noon Eastern time, the stock was hovering around $26 -- still more than 3.5 percent above the previous day’s close, while the rest of the Nasdaq board remained flat.

The announcement led the Piper Jaffray investment house to list Isis as one of its top stock picks, with a target price of $42, although it cautions that more data is needed to see how effective the drug is, noting that other Isis glucose treatments have had issues in the past.

But the firm added that Isis has other attractive assets as well, ranging from a treatment of a rare form of hypercholestorol to a proposed treatment for amyloidosis, a nerve disease that causes pain, numbness and muscular weakness.

Wednesday’s stock surge represents a turnaround for the company, which has fallen 40 percent since March. In a column on Tuesday before the diabetes announcement was made, the Motley Fool investment site said there was no particular event to blame for the decline, and instead suggested that Isis had been “a victim of the wider biotech downturn that hit companies valued more for their clinical, rather than commercial pipeline, particularly hard.” It suggested that Isis might be selling at bargan prices.

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.

User Response
0 UserComments

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.

Isis Pharmaceuticals Inc.

Company Website

1896 Rutherford Road
Carlsbad, CA 92008

Company Trade Data

Stock Symbol Close
Change
Chg %Chg
Volume
52-Week
High Low
ISIS
44.62
  0.68  
+ 1.55%
1,703,078,000
77.8
37.38

Insider Trade Data

Date Insider Shares Type Value
10/02/2015 Parshall, B Lynne 12,436 Sell $506,747
10/02/2015 Parshall, B Lynne 12,436 Exchange $151,720
10/02/2015 Parshall, B Lynne 12,436 Sell $506,747
10/02/2015 Parshall, B Lynne 12,436 Exchange $151,720
07/06/2015 Crooke, Stanley T 12,350 Sell $707,457

Isis Pharmaceuticals Inc. Executive(s):

Stanley Crooke

  • Chairman, Chief Executive Officer, Founder, President

Similar Companies

NAICS - 325414 - Biological Product (except Diagnostic) Manufacturing